Efficacy and Safety of Oral Tranexamic Acid Vs. Other Routes in Total Joint Arthroplasty a Systematic Review and Network Meta-Analysis Publisher Pubmed



Poursalehian M¹ ; Tajvidi M¹ ; Ghaderpanah R¹ ; Soleimani M¹ ; Hashemi SM¹ ; Kachooei AR² Show Affiliations
Source: JBJS Reviews Published:2024

Abstract

Background: Total joint arthroplasty (TJA) is often associated with significant blood loss, leading to complications such as acute anemia and increased risk of infection and mortality. Tranexamic acid (TXA), an antifibrinolytic agent, has been recognized for effectively reducing blood loss during TJA. This systematic review and network meta-analysis aims to evaluate the efficacy and safety of oral TXA compared with other administration routes in TJA. Methods: Adhering to Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, a comprehensive literature search was conducted across multiple databases, including PubMed, Scopus, Embase, and Web of Science, focusing on randomized clinical trials involving oral TXA in TJA. The studies were assessed for quality using the Cochrane risk assessment scale. Data synthesis involved network meta-analyses, comparing outcomes including hemoglobin drop, estimated blood loss (EBL), transfusion rate, and deep vein thrombosis (DVT) rate. Results: Our comprehensive literature search incorporated 39 studies with 7,538 participants, focusing on 8 TXA administration methods in TJA. The combination of oral and intra-articular (oral 1 IA) TXA markedly reduced hemoglobin drop more effectively than oral, intravenous (IV), and IA alone, but the difference was not significant. Oral 1 IA TXA significantly reduced EBL more effectively than oral 1 IV, IA 1 IV, and oral, IV, and IA alone. Perioperative transfusion rates with oral 1 IA TXA was significantly lower than that of oral, IA, and IV alone. The DVT rate with oral 1 IA was significantly lower than that with all other routes, including oral 1 IV, IA 1 IV, and oral, IA, and IV alone. Conclusion: Oral TXA, particularly in combination with IA administration, demonstrates significantly higher efficacy in reducing blood loss and transfusion rates in TJA, with a safety profile comparable with that of other administration routes. The oral route, offering lower costs and simpler administration, emerges as a viable and preferable option in TJA procedures. Level of Evidence: Level I. See Instructions for Authors for a complete description of levels of evidence. COPYRIGHT © 2024 BY THE JOURNAL OF BONE AND JOINT SURGERY, INCORPORATED.